<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314310</url>
  </required_header>
  <id_info>
    <org_study_id>201912245RINB</org_study_id>
    <nct_id>NCT04314310</nct_id>
  </id_info>
  <brief_title>Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia</brief_title>
  <official_title>Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia in Patients Receiving Abdominal and Non-abdominal Surgeries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      breast cancer surgery is associated with a high incidence of persistant postsurgical pain
      (PPSP). The aim of the study was to evluate the impact of intravenous Tenoxicam on acute and
      PPSP, analgesic requirements and gastrointestinal recovery in patients undergoing surgery for
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      thrity patients participated in this randomized, single-blined study. Before and at the
      postoperative day 1, the bowel function (orocecal transmit time) were measured. Before
      induction of general anesthesia, patients recieved a bolus of intravenous Tenoxicam or an
      equal volume of saline (control group). Pain score and opioid consumption were recorded in
      the postoperative period and then daily for 1 week.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>treatment: Tenoxicam; control: placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>care provider and participant were masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>morphine consumption</measure>
    <time_frame>until postoperative day7</time_frame>
    <description>morphine consumption after breast cancer surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>orocecal transmit time,</measure>
    <time_frame>preoperative and postoperative day 1</time_frame>
    <description>smal intestinal function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastrointestinal Recovery</condition>
  <arm_group>
    <arm_group_label>Tenoxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nonsteroidal anti-inflammatory drug (NSAID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>equal volume of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenoxicam</intervention_name>
    <description>nonsteroidal anti-inflammatory drug (NSAID)</description>
    <arm_group_label>Tenoxicam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>equal volume of normal saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I to II Breast cancer patients Mastectomy or wide local excision + axillary note
             dissection

        Exclusion Criteria:

          -  Preexisting malignancy Chronic infection Previous pain condition Diabetes Thyroid
             disorder Severe cardiac, renal or hepatic disease Previous breast surgery Psychiatric
             illness Neurological disease Contraindication for tenoxicam or morphine use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ya-Jung Cheng, MD,PhD</last_name>
    <email>chengyj@ntu.edu.tw</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>orocecal transmit time, flatus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenoxicam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>due to ethical concern</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

